
A New vaccine for celiac disease finished its Phase I trial. The results summary are as follows:
34 test subjects were double blinded to test the safety of the new Nexvax2 vaccine for patients diagnosed with celiac disease. All patients were HLA-DQ 2 or 8 positive. In all, 19 subjects received the vaccine. Three different doses were administered. Side effects were common with higher doses and included:- Nausea
- vomiting
- 1 subject withdrew from the trial due to “severe gastrointestinal symptoms”

